GeneDx announced on October 1, 2025, the launch of BEACONS (Building Evidence and Collaboration for GenOmics in Nationwide Newborn Screening), the first multi-state genomic newborn screening initiative in the U.S. This groundbreaking project is funded by a $14.4 million award from the National Institutes of Health (NIH) Common Fund Venture Program.
BEACONS is a collaboration with Mass General Brigham, Ariadne Labs, Boston Children’s Hospital, and Illumina, among others. The initiative will pilot the integration of whole genome sequencing into existing state newborn screening systems, aiming to enroll up to 30,000 newborns in as many as 10 states over the next three years.
GeneDx will perform the genomic sequencing and interpretation for the study, leveraging its advanced genomic technology and the world’s largest rare disease dataset. This participation positions GeneDx as a critical partner in building a sustainable roadmap for incorporating genome sequencing into U.S. public health practice, with the potential to significantly expand the market for genomic newborn screening.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.